Cargando…
Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs
BACKGROUND: Several sumatriptan subcutaneous autoinjector devices for acute treatment of migraine patients are available, each device differs with respect to design and features. Determining device preference and ease of use is important because patients experiencing a migraine attack are often func...
Autores principales: | Andre, Anthony D, Brand-Schieber, Elimor, Ramirez, Margarita, Munjal, Sagar, Kumar, Rajesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261843/ https://www.ncbi.nlm.nih.gov/pubmed/28176899 http://dx.doi.org/10.2147/PPA.S125137 |
Ejemplares similares
-
Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
por: Brand-Schieber, Elimor, et al.
Publicado: (2016) -
Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine
por: Cady, Roger K., et al.
Publicado: (2017) -
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study
por: Landy, Stephen, et al.
Publicado: (2018) -
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
por: Landy, Stephen, et al.
Publicado: (2018) -
DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment
por: Lipton, Richard B., et al.
Publicado: (2019)